Omega-3 supplementation and outcomes of heart failure: A systematic review of clinical trials
Mahin Nomali,Mohammad Eghbal Heidari,Aryan Ayati,Amirhossein Tayebi,Oksana Shevchuk,Ramin Mohammadrezaei,Hossein Navid,Sayyed Saeid Khayyatzadeh,Svitlana Palii,Fahimeh Valizade Shiran,Atie Sadat Khorasanian,Zahra Veysi,Atena Jamalzehi,Azadeh Lesani,Golnoosh Assari,Shiva Khani,Kamyab Hassanpour,Hadis Gerami
DOI: https://doi.org/10.1097/md.0000000000036804
IF: 1.6
2024-01-20
Medicine
Abstract:Heart failure (HF) is now a worldwide epidemic, with its prevalence and incidence increasing at a fast pace. [ 1 ] According to the American Heart Association data, 8.1 million individuals in the United States are currently suffering from this condition. By 2030, it is anticipated that the global incidence of HF will rise by 46%, emerging as a significant global health concern. [ 1 ] The World Health Organization (2016) has categorized HF as a major contributor to mortality in Europe, pinpointing diet, physical inactivity, smoking, alcohol consumption, hypertension, high cholesterol levels, excess weight, obesity, and diabetes as the primary risk factors. [ 1 ] HF is a consequence of various cardiovascular diseases (CVDs) and continues to be linked with a reduced quality of life (QoL), early mortality, and significant utilization of healthcare resources. [ 2–5 ] Despite the recent advancements in both pharmaceutical and interventional treatments, HF remains a leading cause of mortality and recurrent hospitalization. [ 6 , 7 ] It also serves as a predictor of lethality among geriatric patients. [ 8 ] Omega-3 polyunsaturated fatty acids (ω-3 PUFAs) have emerged as a vital category of dietary lipids that have demonstrated cardiovascular protective properties in HF patients. [ 3 , 9 ]
medicine, general & internal